Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

scientific article published on 07 April 2020

Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1473-3099(19)30611-5
P698PubMed publication ID32275867

P50authorR. Kiplin GuyQ67426629
P2093author name stringLi Tang
John C Panetta
Amber M Smith
James S McCarthy
Patricia M Flynn
Jörg J Möhrle
Burgess B Freeman
Aditya H Gaur
Robbin Christensen
Yvonne Van Gessel
Fabian Gusovsky
Branko Mitasev
Elizabeth John
Stephan Chalon
Ronald H Dallas
John Woodford
Lidiya Bebrevska
Julie L Richardson
Kristen C Branum
Nehali D Patel
Ryan N Heine
Shelley Ost
Tracy B Stewart
P2860cites workNew developments in anti-malarial target candidate and product profilesQ28468598
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugsQ28476638
Chemical genetics of Plasmodium falciparumQ29617272
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.Q30610467
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised studyQ33732740
Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsQ33939069
Spiroindolone KAE609 for falciparum and vivax malariaQ34085717
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteerQ34298776
Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.Q37003081
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteersQ37193141
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection studyQ37254756
Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum MalariaQ37613014
Malaria medicines: a glass half full?Q38497838
A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteersQ41832478
The global fight against malaria is at crossroadsQ48018228
The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational StudyQ50048765
A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection modelQ50318730
Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral DecayQ56000676
P921main subjectmalariaQ12156
Plasmodium falciparumQ311383
pharmacokineticsQ323936
P577publication date2020-04-07
P1433published inLancet Infectious DiseasesQ15724248
P1476titleSafety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Reverse relations

cites work (P2860)
Q91807435Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?
Q104617066Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection

Search more.